Skip to main content

Site notifications

NIMENRIX (Pfizer Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
Meningococcal polysaccharide group W135; Meningococcal polysaccharide group C; Meningococcal polysaccharide Group Y; Tetanus toxoid; Meningococcal polysaccharide group A
Registration type
NIMENRIX (injection) is now indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y.

Help us improve the Therapeutic Goods Administration site